Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
To the Editor—In their article on immunotherapy,
Drs Ballow and Nelson1 omit an important
clinical application of interferon therapy. Adjuvant interferon alfa-2b for
melanoma is now a well-established standard of care among oncologists. The
Eastern Cooperative Oncology Group trial EST 16842
demonstrated that, after resection, patients with lesions of Breslow depth
more than 4 mm and any lesion associated with positive regional lymph nodes,
either clinically or pathologically, experienced up to a 42% increase in disease-free
survival with adjuvant interferon therapy. This also represents an overall
benefit for patients with high-risk lesions.
Nauman C. Interferon for Melanoma: Another Application of Immunopharmacology. JAMA. 1998;279(16):1263. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-16-jac80007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: